Renin Angiotensin Signaling in Normal Pregnancy and Preeclampsia

Seminars in Nephrology

Volumn 31, Issue 1, 2011, Pages 47-58

  Irani, Roxanna A ^a   Xia, Yang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin II; Animal model; Autoimmune; Preeclampsia; Pregnancy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR AGONISTIC AUTOANTIBODY; ANGIOTENSINOGEN; AUTOANTIBODY; ENDOGLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ARTICLE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; INTRACELLULAR SIGNALING; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; NONHUMAN; PLASMA RENIN ACTIVITY; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

ANGIOTENSIN II; ANIMALS; AUTOANTIBODIES; FEMALE; HUMANS; MODELS, ANIMAL; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 78751684734     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.10.005     Document Type: Article

References (92)

1. Jensen B.L., Schmid C., Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol 1996, 271:F659-F669.
2. Chung O., Kuhl H., Stoll M., Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int 1998, 54:S95-S99.
3. Ozono R., Wang Z.Q., Moore A.F., Inagami T., Siragy H.M., Carey R.M. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997, 30:1238-1246.
4. Grishko V., Pastukh V., Solodushko V., Gillespie M., Azuma J., Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol 2003, 285:H2364-H2372.
5. Hagemann A., Nielsen A.H., Poulsen K. The uteroplacental renin-angiotensin system: a review. Exp Clin Endocrinol 1994, 102:252-261.
6. Poisner A.M. The human placental renin-angiotensin system. Front Neuroendocrinol 1998, 19:232-252.
7. Hsueh W.A., Luetscher J.A., Carlson E.J., Grislis G., Fraze E., McHargue A. Changes in active and inactive renin throughout pregnancy. J Clin Endocrinol Metab 1982, 54:1010-1016.
8. Brown M.A., Gallery E.D., Ross M.R., Esber R.P. Sodium excretion in normal and hypertensive pregnancy: a prospective study. Am J Obstet Gynecol 1988, 159:297-307.
9. Merrill D.C., Karoly M., Chen K., Ferrario C.M., Brosnihan K.B. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002, 18:239-245.
10. Oats J.N., Broughton Pipkin F., Symonds E.M. Angiotensin-converting enzyme and the renin-angiotensin system in normotensive primigravid pregnancy. Clin Exp Hypertens B 1982, 1:73-91.
11. Oats J.N., Broughton Pipkin F., Symonds E.M., Craven D.J. A prospective study of plasma angiotensin-converting enzyme in normotensive primigravidae and their infants. Br J Obstet Gynaecol 1981, 88:1204-1210.
12. Hill C.C., Pickinpaugh J. Physiologic changes in pregnancy. Surg Clin North Am 2008, 88:391-401. vii.
13. Langer B., Grima M., Coquard C., Bader A.M., Schlaeder G., Imbs J.L. Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia. Obstet Gynecol 1998, 91:196-202.
14. Assali N.S., Westersten A. Regional flow-pressure relationship in response to angiotensin in the intact dog and sheep. Circ Res 1961, 9:189-193.
15. Abdul-Karim RaA.N. Pressor response to angiotensin in pregnant and non-pregnant women. Am J Obstet Gynecol 1961, 82:246-251.
16. Gant N.F., Worley R.J., Everett R.B., MacDonald P.C. Control of vascular responsiveness during human pregnancy. Kidney Int 1980, 18:253-258.
17. AbdAlla S., Lother H., el Massiery A., Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001, 7:1003-1009.
18. Shibata E., Powers R.W., Rajakumar A., et al. Angiotensin II decreases system A amino acid transporter activity in human placental villous fragments through AT1 receptor activation. Am J Physiol Endocrinol Metab 2006, 291:E1009-E1016.
19. Bobst S.M., Day M.C., Gilstrap L.C., Xia Y., Kellems R.E. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens 2005, 18:330-336.
20. Zhou C.C., Ahmad S., Mi T., Xia L., Abbasi S., Hewett P.W., et al. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007, 100:88-95.
21. Zhou C.C., Ahmad S., Mi T., Abbasi S., Xia L., Day M.C., et al. Autoantibody from women with preeclampsia induces soluble fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008, 51:1010-1019.
22. Zhou C.C., Irani R.A., Zhang Y., Blackwell S.C., Mi T., Wen J., et al. Angiotensin receptor agonistic autoantibody-mediated TNF-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 2010, 121:436-444.
23. Dechend R., Viedt C., Muller D.N., Ugele B., Brandes R.P., Wallukat G., et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003, 107:1632-1639.
24. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
25. Roberts J.M. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998, 16:5-15.
26. Symonds E.M., Broughton Pipkin F., Craven D.J. Changes in the renin-angiotensin system in primigravidae with hypertensive disease of pregnancy. Br J Obstet Gynaecol 1975, 82:643-650.
27. Brown M.A., Zammit V.C., Mitar D.A., Whitworth J.A. Renin-aldosterone relationships in pregnancy-induced hypertension. Am J Hypertens 1992, 5:366-371.
28. Handa R.K. Angiotensin-(1-7) can interact with the rat proximal tubule AT(4) receptor system. Am J Physiol 1999, 277:F75-F83.
29. Handa R.K. Metabolism alters the selectivity of angiotensin-(1-7) receptor ligands for angiotensin receptors. J Am Soc Nephrol 2000, 11:1377-1386.
30. Gant N.F., Daley G.L., Chand S., Whalley P.J., MacDonald P.C. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973, 52:2682-2689.
31. Quitterer U., Lother H., Abdalla S. AT1 receptor heterodimers and angiotensin II responsiveness in preeclampsia. Semin Nephrol 2004, 24:115-119.
32. AbdAlla S., Abdel-Baset A., Lother H., el Massiery A., Quitterer U. Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 2005, 26:185-192.
33. Ariza A.C., Bobadilla N.A., Halhali A. [Endothelin 1 and angiotensin II in preeeclampsia]. Rev Invest Clin 2007, 59:48-56.
34. Zhou Y., Chen Y., Dirksen W.P., Morris M., Periasamy M. AT1b receptor predominantly mediates contractions in major mouse blood vessels. Circ Res 2003, 93:1089-1094.
35. Taugner R., Hackenthal E., Rix E., Nobiling R., Poulsen K. Immunocytochemistry of the renin-angiotensin system: renin, angiotensinogen, angiotensin I, angiotensin II, and converting enzyme in the kidneys of mice, rats, and tree shrews. Kidney Int Suppl 1982, 12:S33-S43.
36. Xia Y., Wen H., Prashner H.R., Chen R., Inagami T., Catanzaro D.F., et al. Pregnancy-induced changes in renin gene expression in mice. Biol Reprod 2002, 66:135-143.
37. Takimoto E., Ishida J., Sugiyama F., Horiguchi H., Murakami K., Fukamizu A. Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 1996, 274:995-998.
38. Saito T., Ishida J., Takimoto-Ohnishi E., Takamine S., Shimizu T., Sugaya T., et al. An essential role for angiotensin II type 1a receptor in pregnancy-associated hypertension with intrauterine growth retardation. FASEB J 2004, 18:388-390.
39. Wallukat G., Homuth V., Fischer T., Lindschau C., Horstkamp B., Jupner A., et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999, 103:945-952.
40. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., McLaughlin M.K. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989, 161:1200-1204.
41. Karumanchi S.A., Epstein F.H. Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia? Kidney Int 2007, 71:959-961.
42. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
43. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993, 90:10705-10709.
44. Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996, 226:324-328.
45. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001, 26:25-35.
46. Zhou Y., McMaster M., Woo K., Janatpour M., Perry J., Karpanen T., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002, 160:1405-1423.
47. Tsatsaris V., Goffin F., Munaut C., Brichant J.-F., Pignon M.-R., Noel A., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003, 88:5555-5563.
48. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.
49. Roberts J.M., Edep M.E., Goldfien A., Taylor R.N. Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence. Am J Reprod Immunol 1992, 27:101-108.
50. Zhou C.C., Zhang Y., Irani R.A., Zhang H., Mi T., Popek E.J., et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008, 14:855-862.
51. Estelles A., Gilabert J., Grancha S., Yamamoto K., Thinnes T., Espana F., et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemost 1998, 79:500-508.
52. Gilabert J., Estelles A., Grancha S., Espana F., Aznar J. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Hum Reprod 1995, 10(Suppl 2):121-131.
53. Xia Y., Wen H., Bobst S., Day M.C., Kellems R.E. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003, 10:82-93.
54. Xia Y., Wen H.Y., Kellems R.E. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation. J Biol Chem 2002, 277:24601-24608.
55. Nakamura S., Nakamura I., Ma L., Vaughan D.E., Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251-259.
56. Fogo A.B. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000, 35:179-188.
57. Petrucco O.M., Thomson N.M., Lawrence J.R., Weldon M.W. Immunofluorescent studies in renal biopsies in pre-eclampsia. Br Med J 1974, 1:473-476.
58. Packham D.K., Mathews D.C., Fairley K.F., Whitworth J.A., Kincaid-Smith P.S. Morphometric analysis of pre-eclampsia in women biopsied in pregnancy and post-partum. Kidney Int 1988, 34:704-711.
59. Erlich J.H., Holdsworth S.R., Tipping P.G. Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis. Am J Pathol 1997, 150:873-880.
60. Xu Y., Berrou J., Chen X., Fouqueray B., Callard P., Sraer J.D., et al. Induction of urokinase receptor expression in nephrotoxic nephritis. Exp Nephrol 2001, 9:397-404.
61. Hubel C.A. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999, 222:222-235.
62. Haller H., Oeney T., Hauck U., Distler A., Philipp T. Increased intracellular free calcium and sensitivity to angiotensin II in platelets of preeclamptic women. Am J Hypertens 1989, 2:238-243.
63. Hojo M., Suthanthiran M., Helseth G., August P. Lymphocyte intracellular free calcium concentration is increased in preeclampsia. Am J Obstet Gynecol 1999, 180:1209-1214.
64. Ray J., Vasishta K., Kaur S., Majumdar S., Sawhney H. Calcium metabolism in pre-eclampsia. Int J Gynaecol Obstet 1999, 66:245-250.
65. Sowers J.R., Zemel M.B., Bronsteen R.A., Zemel P.C., Walsh M.F., Standley P.R., et al. Erythrocyte cation metabolism in preeclampsia. Am J Obstet Gynecol 1989, 161:441-445.
66. Thway T.M., Shlykov S.G., Day M.C., Sanborn B.M., Gilstrap L.C., Xia Y., et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004, 110:1612-1619.
67. Dechend R., Homuth V., Wallukat G., Kreuzer J., Park J.K., Theuer J., et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000, 101:2382-2387.
68. Dorffel Y., Wallukat G., Bochnig N., Homuth V., Herberg M., Dorffel W., et al. Agonistic AT(1) receptor autoantibodies and monocyte stimulation in hypertensive patients. Am J Hypertens 2003, 16:827-833.
69. Dechend R., Gratze P., Wallukat G., Shagdarsuren E., Plehm R., Brasen J.H., et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005, 45:742-746.
70. Granger J.P., LaMarca B.B., Cockrell K., Sedeek M., Balzi C., Chandler D., et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 2006, 122:383-392.
71. Dechend R., Llinas M., Caluwaerts S., Herse F., Lamarca B., Mueller D.N., et al. Agonistic autoantibodies to the AT1 receptor in rat models of preeclampsia: induced by chronic reduction in uterine perfusion pressure (RUPP) and low dose TNF-a infusion [abstract]. Hypertens Pregnancy 2006, 25:70.
72. Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003, 69:1-7.
73. Ness R.B., Sibai B.M. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006, 195:40-49.
74. Oliverio M.I., Best C.F., Kim H.S., Arendshorst W.J., Smithies O., Coffman T.M. Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. Am J Physiol 1997, 272:F515-F520.
75. Furuya M., Ishida J., Inaba S., Kasuya Y., Kimura S., Nemori R., et al. Impaired placental neovascularization in mice with pregnancy-associated hypertension. Lab Invest 2008, 88:416-429.
76. Irani R.A., Zhang Y., Blackwell S.C., Zhou C.C., Ramin S.M., Kellems R.E., et al. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J Exp Med 2009, 206:2809-2822.
77. Pearce S.H., Merriman T.R. Genetic progress towards the molecular basis of autoimmunity. Trends Mol Med 2006, 12:90-98.
78. Fujinami R.S., von Herrath M.G., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006, 19:80-94.
79. Barak Y. The immune system and happiness. Autoimmun Rev 2006, 5:523-527.
80. Siddiqui A.H., Irani R.A., Blackwell S.C., Ramin S.M., Kellems R.E., Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia. Correlation with disease severity. Hypertension 2010, 55:386-393.
81. Hubel C.A., Wallukat G., Wolf M., Herse F., Rajakumar A., Roberts J.M., et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007, 49:612-617.
82. Sattar N., Greer I.A. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002, 325:157-160.
83. Wilson B.J., Watson M.S., Prescott G.J., Sunderland S., Campbell D.M., Hannaford P., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003, 326:845.
84. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007, 335:974.
85. Smith G.C., Pell J.P., Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001, 357:2002-2006.
86. Irgens H.U., Reisaeter L., Irgens L.M., Lie R.T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001, 323:1213-1217.
87. Suzuki S., Gejyo F., Ogino S., Maruyama Y., Ueno M., Nishi S., et al. Postpartum renal lesions in women with pre-eclampsia. Nephrol Dial Transplant 1997, 12:2488-2493.
88. Bar J., Kaplan B., Wittenberg C., Erman A., Boner G., Ben-Rafael Z., et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant 1999, 14:1129-1132.
89. Agatisa P.K., Ness R.B., Roberts J.M., Costantino J.P., Kuller L.H., McLaughlin M.K. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004, 286:H1389-H1393.
90. Herse F., Dechend R., Harsem N.K., Wallukat G., Janke J., Qadri F., et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007, 49:604-611.
91. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
92. Shaarawy M., Didy H.E. Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynaecol Obstet 1996, 55:135-139.